In the past 4  years, five new agents have been approved for metastatic, castration-resistant @entity263 . Four of them are non-chemotherapeutic and generally well tolerated. However, each has @entity137 that can negatively impact @entity1 , particularly the elderly. This review covers the epidemiology of @entity263 in elderly @entity1 . It discusses the efficacy data for sipuleucel-T, @entity17931 in chemotherapy-na  ve @entity1 , @entity14164 in chemotherapy-na  ve @entity1 and radium-223 and presents any additional studies done for those over 75  years of age. Disease burden, such as the presence or absence of @entity66 , and comorbid conditions weigh into the selection of therapy and are discussed here. Drug-drug interactions between these agents and other drugs commonly used in the elderly population are also considered. The emerging therapies tasquinimod and ipilimumab are reviewed. With the arrival of so many agents for @entity263 , selection of the most appropriate agent can be perplexing, particularly because these agents were tested against placebo, not one another. Furthermore, the study population differs significantly from those seen in clinical practice. This review addresses these issues.

Pharmacotherapeutic management of metastatic, castration-resistant XXXX in the elderly: focus on non-chemotherapy agents.

@entity1 :: ('9606', 'Species') :: ['patients', 'men'] @entity17931 :: ('MESH:C089740', 'Chemical') :: ['abiraterone'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities'] @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer'] @entity66 :: ('MESH:D004194', 'Disease') :: ['visceral disease'] @entity14164 :: ('MESH:C540278', 'Chemical') :: ['enzalutamide']
@entity263 :: (MESH:D011471,Disease) :: ['prostate cancer']
